China

Innovator drug deals involving Chinese biopharma reach $41.5 billion as licensing overtakes M&A for pipeline expansion, notes…

The company expands its global footprint with regulatory approval from China’s NMPA, reinforcing its leadership in antihistamine…

China represents the largest market for data and analytics in the pharmaceutical sector, contributing roughly 20.2 per cent of…

By FY 2023, Chinese imports accounted for 64 per cent of India’s IPA supply. Vikas Biyani – FDA Regulatory Consultant states that…

Leqembi is the only approved treatment in China that has shown efficacy in slowing the progression of Alzheimer’s by directly…

China is the third country to launch LEQEMBI following the US and Japan

The lawmakers wrote that theinspection outcomes were the opposite of what would be expected given the poor quality control and…

Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy reduced the risk of disease progression or death by…

Preliminary results from the Phase I study demonstrated promising efficacy in pancreatic ductal adenocarcinoma and the bispecific…

The company said its independently developed mRNA vaccine SYS6006 targets some major Omicron variants and its booster dose showed…